Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aligos Therapeutics ( (ALGS) ) just unveiled an announcement.
On April 16, 2026, Aligos Therapeutics entered into a license agreement with Xiamen Amoytop Biotech granting Amoytop exclusive rights to manufacture, develop and commercialize Aligos’ investigational hepatitis B compound pevifoscorvir sodium in mainland China, Taiwan, Hong Kong and Macau for hepatitis B and hepatitis B/D co-infection, while Aligos retains rights for use outside that territory and outside the licensed field. The deal, which is subject to Amoytop shareholder approval within 45 days, includes a $25 million upfront payment, up to $420 million in potential milestones and tiered high single-digit royalties, transfers development, regulatory, manufacturing and commercialization responsibilities in the territory to Amoytop, and establishes broad data and intellectual property sharing that could strengthen Aligos’ capsid assembly modulator portfolio globally and deepen its strategic presence in Asian hepatitis markets.
The agreement outlines detailed royalty terms, sublicense participation and conditions under which either party may terminate or suspend activities for safety, regulatory or breach-related reasons, providing a structured risk-sharing framework for both companies. By securing a well-capitalized regional partner with obligations to meet development and commercialization milestones, Aligos positions pevifoscorvir sodium for potential acceleration in major hepatitis B markets while preserving upside from ex-China rights and access to Amoytop-generated know-how for its broader antiviral pipeline.
The most recent analyst rating on (ALGS) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.
Spark’s Take on ALGS Stock
According to Spark, TipRanks’ AI Analyst, ALGS is a Neutral.
The score is held down primarily by very weak financial performance (zero revenue, ongoing large losses, and sustained cash burn with financing risk). Technicals remain soft with the stock below major moving averages, and valuation is constrained by unprofitability and no dividend support. Offsetting these, corporate events are a notable positive due to Phase 2 progress and Fast Track designation.
To see Spark’s full report on ALGS stock, click here.
More about Aligos Therapeutics
Aligos Therapeutics, Inc. is a biopharmaceutical company focused on developing antiviral therapies, including capsid assembly modulators, for chronic hepatitis B and related viral infections. The company leverages partnerships and licensing arrangements to advance its investigational compounds and expand access in key markets, particularly in Asia where hepatitis B remains highly prevalent.
Average Trading Volume: 52,599
Technical Sentiment Signal: Sell
Current Market Cap: $45.91M
See more insights into ALGS stock on TipRanks’ Stock Analysis page.